Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. CA2781549 - NORMALISATION DE BIOMARQUEURS DE PLAQUETTES

Office
Canada
Numéro de la demande 2781549
Date de la demande 23.11.2010
Numéro de publication 2781549
Date de publication 26.05.2011
Type de publication A1
CIB
G01N 33/68
GPHYSIQUE
01MÉTROLOGIE; TESTS
NRECHERCHE OU ANALYSE DES MATÉRIAUX PAR DÉTERMINATION DE LEURS PROPRIÉTÉS CHIMIQUES OU PHYSIQUES
33Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes G01N1/-G01N31/146
48Matériau biologique, p.ex. sang, urine; Hémocytomètres
50Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
68faisant intervenir des protéines, peptides ou amino-acides
G06F 17/00
GPHYSIQUE
06CALCUL; COMPTAGE
FTRAITEMENT ÉLECTRIQUE DE DONNÉES NUMÉRIQUES
17Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des fonctions spécifiques
G06F 19/00
GPHYSIQUE
06CALCUL; COMPTAGE
FTRAITEMENT ÉLECTRIQUE DE DONNÉES NUMÉRIQUES
19Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques
CPC
G01N 33/6887
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6887from muscle, cartilage or connective tissue
G01N 33/74
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
74involving hormones ; or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
G01N 33/80
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
80involving blood groups or blood types ; or red blood cells
G01N 33/96
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
96involving blood or serum control standard
Déposants CHILDREN'S MEDICAL CENTER CORPORATION
ORTHO-CLINICAL DIAGNOSTICS, INC.
THE BRIGHAM AND WOMEN'S HOSPITAL, INC
Inventeurs PETERSON, JON
KLEMENT, GIANNOULA
ITALIANO, JOSEPH
DOWNING, SEAN
Données relatives à la priorité 61/263,686 23.11.2009 US
Titre
(EN) NORMALIZATION OF PLATELET BIOMARKERS
(FR) NORMALISATION DE BIOMARQUEURS DE PLAQUETTES
Abrégé
(EN)
Described herein are methods useful for normalizing any biomarker in platelets. This has application in any method in which one wishes to ascertain or compare the level of a biomarker, e.g., for diagnostic or prognostic methods relating to a biomarker of interest. Using such an approach can permit the assessment of disease status (e.g., angiogenic status) of an individual with less error than an expression value that is not normalized or that is normalized to total protein levels. Also provided are methods for selecting a normalizing protein for normalizing biomarkers in a sample, e.g., a platelet sample.

Également publié en tant que